On 16 November, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, Illinois, US, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE. This trial involved 703 patients with heterozygous familial hypercholesterolemia (HeFH), identified […]
At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed. Significant advancements and remaining hurdles in vaccination strategies and outbreak management were highlighted, particularly about high-risk communities and regions with limited healthcare infrastructure.
IDWeek 2024: strategic approaches and challenges in mpox vaccination Read More »
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024. These companies reported a total market capitalisation
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals Read More »
On October 24, Dyno Therapeutics announced the formation of a new strategic partnership with Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. The utilisation of AI is a key industry trend in the development of
Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders Read More »
At IDWeek 2024 [the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists], which took place
Kalihinol analogue shows promise as targeted antimalarial therapy Read More »
The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the well-being of marginalised communities affected by this practice today. Redlining, a
Redlining’s lasting impact on asthma disparities Read More »
The EU is considering creating a Critical Medicines Act to secure Europe’s supplies of pharmaceuticals. Europe is swiftly revising its laws and policies concerning critical medicines as the region seeks to tackle shortages and a reliance on China. In 2023/24,
closer to ending overreliance on Asia Read More »
On 21 October 2024, at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, a matching-adjusted meta-analysis that indirectly compared the efficacies of Eylea HD (aflibercept 8mg) and Vabysmo (faricimab) was presented by Dr
NMA reveals Vabysmo’s superior CST improvement over Eylea HD Read More »
On 20 October 2024, the International Osteoporosis Foundation (IOF) led global observances for World Osteoporosis Day, with a focus on the need for heightened awareness and prevention of osteoporosis. This year’s campaign, “Say no to fragile bones,” focused on proactive
World Osteoporosis Day calls for action to prevent fragility fractures Read More »
On 20 October, two-year data from Nanoscope Therapeutics’ Phase IIb/III trial for their Multi-Characteristic Opsin (MCO-010) (RESTORE; NCT04945772), was presented at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago. This trial investigated the potential
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients Read More »
